Literature DB >> 1537055

Effect of anticancer drugs on the release of interleukin-6 in vitro.

S I Hasan1, B A Blaney, J L Turk.   

Abstract

This study investigates the effects of anticancer drugs and immunomodulating agents on the release of interleukin-6 (IL-6) from lipopolysaccharide-stimulated human peripheral blood mononuclear leucocytes in vitro. The addition of non-cytotoxic concentrations of Adriamycin (doxorubicin), vincristine and 4-OOH-cyclophosphamide (the in vitro active analogue of cyclophosphamide) resulted in suppression of IL-6 release. The drugs bleomycin, FK156 [D-lactoyl-L-alanyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(L)-g lycine], FK565 [heptanoyl-gamma-D-glutamyl-(L)-meso-diaminopimelyl-(D)-alan ine] and the immunosuppressive agent cyclosporin A did not alter the release of IL-6 in the same experimental system.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1537055     DOI: 10.1007/bf01741790

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  35 in total

1.  Potentiation of release of interleukin-2 by bleomycin.

Authors:  T A Abdul Hamied; D Parker; J L Turk
Journal:  Immunopharmacology       Date:  1986-10

2.  Effect of anticancer drugs on the release of interferon gamma in vitro.

Authors:  K Ahmed; P H van der Meide; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma.

Authors:  X G Zhang; B Klein; R Bataille
Journal:  Blood       Date:  1989-07       Impact factor: 22.113

4.  Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro.

Authors:  K Ahmed; J L Turk
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

5.  Mitogenic potentials of bestatin, amastatin, arphamenines A and B, FK-156 and FK-565 on spleen lymphocytes.

Authors:  N Weissmann; G Leyhausen; A Maidhof; W Tanaka; H Umezawa; W E Müller
Journal:  J Antibiot (Tokyo)       Date:  1985-06       Impact factor: 2.649

6.  Effect of antineoplastic drugs on human leukocyte-mediated cytotoxicity against herpes simplex virus infected cells.

Authors:  R Bolivar; S Kohl; L K Pickering; D L Walters
Journal:  Cancer       Date:  1980-10-01       Impact factor: 6.860

7.  Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin.

Authors:  T Hirano; K Yasukawa; H Harada; T Taga; Y Watanabe; T Matsuda; S Kashiwamura; K Nakajima; K Koyama; A Iwamatsu
Journal:  Nature       Date:  1986 Nov 6-12       Impact factor: 49.962

8.  B cell stimulatory factor-2 is involved in the differentiation of cytotoxic T lymphocytes.

Authors:  Y Takai; G G Wong; S C Clark; S J Burakoff; S H Herrmann
Journal:  J Immunol       Date:  1988-01-15       Impact factor: 5.422

9.  Synergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha.

Authors:  A G Leary; K Ikebuchi; Y Hirai; G G Wong; Y C Yang; S C Clark; M Ogawa
Journal:  Blood       Date:  1988-06       Impact factor: 22.113

10.  Effect of anticancer drugs on the release of interleukin-3 in vitro.

Authors:  S I Hasan; J L Turk
Journal:  Int J Immunopharmacol       Date:  1991
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.